DOCSLIB.ORG

Randomized Comparison of Cilostazol Vs Ticlopidine for Antiplatelet Therapy After Coronary Stenting

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Randomized Comparison of Cilostazol Vs Ticlopidine for Antiplatelet Therapy After Coronary Stenting Circ J 2005; 69: 780–785 Randomized Comparison of Cilostazol vs Ticlopidine for Antiplatelet Therapy After Coronary Stenting Noriyuki Takeyasu, MD; Shigeyuki Watanabe, MD*; Yuichi Noguchi, MD; Kimito Ishikawa, MD; Yuko Fumikura, MD; Iwao Yamaguchi, MD* Background Cilostazol and ticlopidine are commonly prescribed for prevention of thrombosis after coronary stenting, but few studies have compared them. Methods and Results In the present study 642 patients who underwent stenting were randomized to treatment either with cilostazol+aspirin (C group, 321 patients) or ticlopidine+aspirin (T group, 321 patients). Quantita- tive coronary angiography (QCA) was performed immediately after stenting and at the 6-month follow-up. Treatment was continued until follow-up angiography. Baseline patient characteristics did not differ signifi- cantly. With the exception of a higher rate of stenting in a venous graft in the C group, there were no differences in angiographic characteristics or stent type. Baseline QCA analysis of the reference diameter, minimal lumen diameter (MLD) showed no significant differences. Follow-up QCA analysis of the MLD showed no significant differences. There were also no differences in restenosis or target lesion revascularization rates, or in the inci- dence of adverse reactions. However, the rate of subacute thrombosis (SAT) was significantly higher in the C group than in the T group (2% vs 0.3%, p=0.02). Conclusion In the present study there was a similar restenosis rate with cilostazol or ticlopidine, but the rate of SAT was significantly higher with cilostazol. There was no significant difference in adverse reactions. (Circ J 2005; 69: 780–785) Key Words: Adverse drug reaction; Cilostazol; Coronary stenting; Subacute thrombosis; Ticlopidine tent implantation reduced the rates of acute occlusion world”. and restenosis after percutaneous coronary inter- We therefore designed the present study to evaluate and S vention (PCI),1 but a new type of problem emerged, compare the clinical effects of cilostazol vs ticlopidine namely, subacute thrombosis (SAT) within the stent and it after stent implantation with respect to SAT rate, restenosis is again highlighted in the present drug-eluting-stent era. rate, cardiac events, and ADR in consecutive patients Colombo et al reported that after stent implantation, anti- undergoing emergency PCI, including acute coronary coagulants can be replaced by a combination of antiplatelet syndrome (ACS). therapy with ticlopidine and aspirin.2,3 However, serious adverse drug reactions (ADR), including hepatic dysfunc- tion, granulocytopenia, interstitial pneumonia and throm- Methods botic thrombocytopenic purpura (TTP), have been reported Patients Selection and Drug Regimens with ticlopidine.4–6 Between August 1997 and January 2002, 642 consecu- Cilostazol, similar to ticlopidine, is used to prevent SAT tive patients with ischemic heart disease who underwent after stent implantation and is also expected to reduce the revascularization by implantation of coronary stent were incidence of restenosis,7,8 with milder adverse effects than randomized to treatment with cilostazol 200 mg/day + ticlopidine. Yoon et al reported that antiplatelet therapy aspirin (C group, 321 patients) or ticlopidine 200mg/day+ with cilostazol+aspirin was as effective as ticlopidine+ aspirin (T group, 321 patients). The randomization was aspirin in preventing stent thrombosis and there was no performed with a standard list of random numbers. The statistical difference in the incidence of ADR and compli- administration of the antiplatelet agents was open label (ie, cations.9 However, those patients had undergone elective the physicians and patients were not blinded). Treatment coronary stenting, so it remains unclear whether antiplate- was continued for at least 6 months after stent implantation let therapy with cilostazol+aspirin is equally effective as until follow-up angiography was performed. Oral aspirin ticlopidine+aspirin in emergency PCI cases in the “real was started at a dose of 81–200mg/day prior to the proce- dure, and oral cilostazol or ticlopidine was started 2h after (Received January 26, 2005; revised manuscript received April 13, stent implantation. Heparin was administered during the 2005; accepted May 2, 2005) PCI, but was continued for 2 or 3 days after the procedure Cardiovascular Division, Department of Internal Medicine, Tsukuba only in patients with acute myocardial infarction. Warfarin Medical Center Hospital, *Medical Science for Control of Pathologi- was not prescribed. A variety of stents were used for im- cal Processes, Graduate School of Comprehensive Human Sciences, plantation at the lesion site, with selection left to the discre- University of Tsukuba, Tsukuba, Japan Mailing address: Shigeyuki Watanabe, MD, Graduate School of tion of the treating physician. Exclusion criteria included Comprehensive Human Sciences, University of Tsukuba, 1-1-1 active hepatitis or liver cirrhosis, active internal bleeding, Tennoudai, Tsukuba, Ibaraki 305-8575, Japan. E-mail: s-watanabe@ or an absolute contraindication to anticoagulation. The md.tsukuba.ac.jp study protocol was approved by the Institutional Review Circulation Journal Vol.69, July 2005 Cilostazol vs Ticlopidine After Stenting 781 Board of Tsukuba Medical Center Hospital and written Table 1 Patient Characteristics informed consent was obtained from all subjects before T group C group p value randomization. (n=321) (n=321) Definitions Lesions, n 436 428 Age, years 65.2±10.4 65.1±10.4 NS Restenosis was defined as >50% diameter stenosis at the Male, n (%) 242 (75%) 255 (79%) NS intervention site on follow-up angiography. The diagnosis Medical history, n (%) of distal embolism was based on angiographic cut-off of a Hypertension 244 (76%) 231 (72%) NS distal branch or vessel at any point during the procedure Diabetes 177 (55%) 170 (53%) NS and/or decreased flow in a distal vessel that was previously Hyperlipidemia 228 (71%) 215 (67%) NS patent in the absence of an occlusion at the site of the target Smoking 247 (77%) 238 (74%) NS Previous MI 138 (43%) 147 (46%) NS lesion. SAT was defined as angiographic documentation of CABG 12 (4%) 14 (4%) NS stent occlusion within 30 days of the procedure compared Diagnosis, n (%) with after 24h, and acute thrombosis was defined as stent ACS 112 (35%) 103 (32%) NS occlusion within 24h. The occurrence of ADR including AP 219 (65%) 218 (68%) NS rash, purpura, diarrhea, nausea, gastrointestinal bleeding, Data are the number (%) of patients or mean value ± SD. cytopenia, hepatic dysfunction and renal dysfunction were ACS, acute coronary syndrome; MI, myocardial infarction; CABG, coronary prospectively monitored. Neutropenia was defined as artery bypass grafting; AP, angina pectoris. neutrophil count <1,200/mm3 and thrombocytopenia as a reduction in the platelet count to <80,000/mm3 or a rela- tive reduction of the platelet count to <50% of baseline. analysis to compare the QCA values. The Mann-Whitney Hepatic dysfunction was defined as an increase of aspartate U test or chi-square test was used to analyze comparisons transaminase or alanine transaminase more than 2-fold the of baseline clinical and angiographic characteristics. A p- upper limit of normal and renal dysfunction as an increase value less than 0.05 was considered statistically significant. of serum creatinine >0.5 mg/dl above baseline. Hema- tologic status was evaluated every 2 or 4 weeks after the first administration of the drug. If patients had any side Results effects, the study drug was discontinued. Baseline Characteristics There were 436 target lesions in the T group and 428 tar- Angiographic Analysis and Follow-up get lesions in the C group. Baseline characteristics includ- Quantitative coronary angiography was performed ing age, gender, coronary risk factors did not significantly (QCA; Quantocor, Siemens, Erlangen, Germany) at base- differ between the 2 groups (Table 1), nor were there line (before and immediately after procedure) and at 6- significant differences in a history of myocardial infarction month follow-up to measure the reference diameter and or coronary artery bypass surgery. The number of patients minimal lumen diameter (MLD) of the lesion site, percent diagnosed as ACS at the time of procedure was not signifi- stenosis, and lesion length. In addition, the restenosis rates, cantly different between the groups. target lesion revascularization (TLR) rates, acute thrombo- sis and SAT rates, and incidence of ADR were compared Angiographic Characteristics, Stent Type and Stent between the 2 treatment groups. Implantation Procedure Characteristics Follow-up endpoints included restenosis, acute throm- With the exception of a higher rate of stent implantation bosis or SAT, reintervention at the stent placement site, in a venous graft in the C group (4 patients) compared with and serious ADR. the T group (0 patients), there were no other significant differences in the angiographic characteristics between the Statistical Analysis 2 groups (Table2). The lesion types at the stent placement All values are expressed as the mean±standard devia- site did not significantly differ, nor was there a significant tion. Repeated-measure ANOVA was used for statistical difference in the type of the stent implanted or the stent Table 2 Angiographic Characteristics T group C group p value (n=436 lesions), n (%) (n=427 lesions), n (%) Artery stented LAD 215 (49%) 203 (48%) NS LCX 76 (17%) 61 (14%) NS RCA 139 (32%) 155 (36%) NS LMT 5 (1%) 3 (1%) NS SVG 0 (0%) 4 (1%) 0.04 LITA or RITA 1 (0.2%) 1 (0.2%) NS Lesion type A 118 (27%) 103 (24%) NS B1 101 (23%) 111 (26%) NS B2 108 (25%) 115 (27%) NS C 109 (25%) 98 (23%) NS Data are the number (%) of lesions. LAD, left anterior descending artery; LCX, left circumflex artery; RCA, right coronary artery; LMT, left main coronary trunk; SVG, saphenous vein graft; LITA, left internal thoracic artery; RITA, right internal thoracic artery. Circulation Journal Vol.69, July 2005 782 TAKEYASU N et al. T group (436 lesions) C group (427 lesions) Cordis Ter umo Cordis 2 (0.5%) 1 (0.2%) 1 (0.2%) PS PS GFX 50 (13%) GFX 58 (14%) 57 (13%) 58 (14%) Wiktor Wiktor 30 (7%) 30 (7%) ML ML 89 (20%) 91 (21%) NIR NIR 193 (44%) 204 (48%) Fig1.
Load more

Recommended publications
  • Ticlopidine in Its Prodrug Form Is a Selective Inhibitor of Human Ntpdase1
    Hindawi Publishing Corporation Mediators of Inflammation Volume 2014, Article ID 547480, 8 pages http://dx.doi.org/10.1155/2014/547480 Research Article Ticlopidine in Its Prodrug Form Is a Selective Inhibitor of Human NTPDase1 Joanna Lecka,1,2 Michel Fausther,1,2 Beat Künzli,3 and Jean Sévigny1,2 1 Departement´ de Microbiologie-Infectiologie et d’Immunologie, FacultedeM´ edecine,´ UniversiteLaval,Qu´ ebec,´ QC, Canada G1V 0A6 2 Centre de Recherche du CHU de Quebec,´ 2705 Boulevard Laurier, Local T1-49, Quebec,´ QC, Canada G1V 4G2 3 Department of Surgery, Klinikum Rechts der Isar, Technische Universitat¨ Munchen,¨ 81675 Munich, Germany Correspondence should be addressed to Jean Sevigny;´ [email protected] Received 12 May 2014; Accepted 21 July 2014; Published 11 August 2014 Academic Editor: Mireia Mart´ın-Satue´ Copyright © 2014 Joanna Lecka et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Nucleoside triphosphate diphosphohydrolase-1 (NTPDase1), like other ectonucleotidases, controls extracellular nucleotide levels and consequently their (patho)physiological responses such as in thrombosis, inflammation, and cancer. Selective NTPDase1 inhibitors would therefore be very useful. We previously observed that ticlopidine in its prodrug form, which does not affect P2 receptor activity, inhibited the recombinant form of human NTPDase1 ( =14M). Here we tested whether ticlopidine can be used as a selective inhibitor of NTPDase1. We confirmed that ticlopidine inhibits NTPDase1 in different forms and in different assays. The ADPase activity of intact HUVEC as well as of COS-7 cells transfected with human NTPDase1 was strongly inhibited by 100 M ticlopidine, 99 and 86%, respectively.
    [Show full text]
  • Health Reports for Mutual Recognition of Medical Prescriptions: State of Play
    The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11.
    [Show full text]
  • A Comparative Study of Molecular Structure, Pka, Lipophilicity, Solubility, Absorption and Polar Surface Area of Some Antiplatelet Drugs
    International Journal of Molecular Sciences Article A Comparative Study of Molecular Structure, pKa, Lipophilicity, Solubility, Absorption and Polar Surface Area of Some Antiplatelet Drugs Milan Remko 1,*, Anna Remková 2 and Ria Broer 3 1 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Comenius University in Bratislava, Odbojarov 10, SK-832 32 Bratislava, Slovakia 2 Department of Internal Medicine, Faculty of Medicine, Slovak Medical University, Limbová 12, SK–833 03 Bratislava, Slovakia; [email protected] 3 Department of Theoretical Chemistry, Zernike Institute for Advanced Materials, University of Groningen, Nijenborgh 4, 9747 AG Groningen, The Netherlands; [email protected] * Correspondence: [email protected]; Tel.: +421-2-5011-7291 Academic Editor: Michael Henein Received: 18 February 2016; Accepted: 11 March 2016; Published: 19 March 2016 Abstract: Theoretical chemistry methods have been used to study the molecular properties of antiplatelet agents (ticlopidine, clopidogrel, prasugrel, elinogrel, ticagrelor and cangrelor) and several thiol-containing active metabolites. The geometries and energies of most stable conformers of these drugs have been computed at the Becke3LYP/6-311++G(d,p) level of density functional theory. Computed dissociation constants show that the active metabolites of prodrugs (ticlopidine, clopidogrel and prasugrel) and drugs elinogrel and cangrelor are completely ionized at pH 7.4. Both ticagrelor and its active metabolite are present at pH = 7.4 in neutral undissociated form. The thienopyridine prodrugs ticlopidine, clopidogrel and prasugrel are lipophilic and insoluble in water. Their lipophilicity is very high (about 2.5–3.5 logP values). The polar surface area, with regard to the structurally-heterogeneous character of these antiplatelet drugs, is from very large interval of values of 3–255 Å2.
    [Show full text]
  • Cilostazol Protects Rats Against Alcohol‑Induced Hepatic Fibrosis Via Suppression of TGF‑Β1/CTGF Activation and the Camp/Epac1 Pathway
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 17: 2381-2388, 2019 Cilostazol protects rats against alcohol‑induced hepatic fibrosis via suppression of TGF‑β1/CTGF activation and the cAMP/Epac1 pathway KUN HAN, YANTING ZHANG and ZHENWEI YANG Department of Gastroenterology, Xi'an Central Hospital, Xi'an, Shaanxi 710003, P.R. China Received July 2, 2018; Accepted November 23, 2018 DOI: 10.3892/etm.2019.7207 Abstract. Alcohol abuse and chronic alcohol consump- Introduction tion are major causes of alcoholic liver disease worldwide, particularly alcohol‑induced hepatic fibrosis (AHF). Liver Liver fibrosis is a wound‑healing response to a variety of liver fibrosis is an important public health concern because of its insults, including excessive alcohol intake. Alcohol abuse and high morbidity and mortality. The present study examined chronic alcohol consumption are major causes of alcoholic the mechanisms and effects of the phosphodiesterase III liver disease (ALD) worldwide (1). Alcohol‑induced hepatic inhibitor cilostazol on AHF. Rats received alcohol infu- fibrosis (AHF) may cause serious hepatic cirrhosis, and is sions via gavage to induce liver fibrosis and were treated widely accepted as a milestone event in ALD (2). However, with colchicine (positive control) or cilostazol. The serum recent evidence indicates that liver fibrosis is reversible and alcohol dehydrogenase (ADH) and acetaldehyde dehydro- that the liver may recover from cirrhosis (3). Therefore, eluci- genase (ALDH) activities and the albumin/globulin (A/G), dation of the cellular and molecular mechanisms is urgently enzymes and hyaluronic acid (HA), type III precollagen required to prevent AHF. (PC III), laminin (LA), and type IV collagen (IV‑C) levels The exact mechanism remains unclear, but certain changes were measured using commercially available kits.
    [Show full text]
  • Preventive Medication Program
    PREVENTIVE MEDICATION PROGRAM Generics and Preferred Brands Drug List Starting July 1, 2021 Preventive medications are used to prevent certain conditions from developing, or to prevent a condition from coming back. These conditions include, but are not limited to, asthma, depression, diabetes, heart attack, high blood pressure, high cholesterol, osteoporosis, prenatal nutrient deficiency and stroke. About this drug list. Your cost-share for preventive generic and This is a list of the most commonly prescribed generic preferred brand medications. and preferred brand medications that are part of Not all plans offer the same cost-share for their Cigna’s preventive medication program as of July preventive medication program. For example, some 1, 2021.1,2 This drug list is updated often so it isn’t a plans may require you to pay a copay, coinsurance complete list of medications. Also, your specific plan’s and/or deductible for preventive generic and preferred preventive medication program may not include all brand medications; other plans may not. of these medications and/or conditions. Log in to the Log into the myCigna App or myCigna.com and use myCigna® App or myCigna.com, or check your plan the Price a Medication tool to see how much your materials, to see all of the medications included in your medication may cost you at the different pharmacies in plan’s preventive medication program and how much your plan’s network.3 they cost. Here’s some helpful information about this drug list: › Medications are listed alphabetically by condition. › Brand-name medications are capitalized and generic medications are lowercase.
    [Show full text]
  • Wo 2010/075090 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 July 2010 (01.07.2010) WO 2010/075090 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 409/14 (2006.01) A61K 31/7028 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 409/12 (2006.01) A61P 11/06 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2009/068073 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 15 December 2009 (15.12.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/122,478 15 December 2008 (15.12.2008) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): AUS- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, PEX PHARMACEUTICALS, INC.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Preventive Generic Drugs Listing
    2017 PREVENTIVE DRUG LIST Preventive medications are used for the prevention of conditions such as high blood pressure, high cholesterol, diabetes, asthma, osteoporosis, heart attack, stroke and prenatal nutrient deficiency. You may not have to pay a copay, a coinsurance (the percentage you pay after you meet your deductible) and/or a deductible (the amount you pay before your plan starts to pay) for preventive medications. Please check your plan’s prescription drug list and This list is subject to change and may not include all plan documents to understand how your plan covers preventive medications that your plan covers. Please preventive medications. You can refer to myCigna.com refer to your plan’s prescription drug list for a complete for a complete and up-to-date drug listing for your plan. and up-to-date drug listing. You can also use the Prescription Drug Price Quote tool on myCigna.com to view and compare drug prices. The following is a list of generic and brand-name If you have questions preventive medications, arranged by type of condition. Please call the toll-free number on the back of Talk with your doctor when choosing the preventive your Cigna ID card. We’re here to help. medication that is right for you. Also talk with your doctor about available generic preventive medications (listed as uncapitalized medications and/or in parentheses). Generic medications have the same active ingredients, dosage form, quality and strength, as their brand-name counterparts and may provide additional savings for you. Offered by: Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, or their affiliates.
    [Show full text]
  • Cilostazol Tablets, USP50 Mg and 100 Mgrx Only
    CILOSTAZOL - cilostazol tablet Physicians Total Care, Inc. ---------- Cilostazol Tablets, USP 50 mg and 100 mg Rx only CONTRAINDICATION Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III. Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III-IV congestive heart failure. Cilostazol is contraindicated in patients with congestive heart failure of any severity. DESCRIPTION Cilostazol is a quinolinone derivative that inhibits cellular phosphodiesterase (more specific for phosphodiesterase III). The empirical formula of cilostazol is C20H27N5O2, and its molecular weight is 369.46. Cilostazol is 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone, CAS-73963-72-1. The structural formula is: Cilostazol occurs as white to off-white crystals or as a crystalline powder that is slightly soluble in methanol and ethanol, and is practically insoluble in water, 0.1 N HCl, and 0.1 N NaOH. Cilostazol Tablets, USP for oral administration are available as 50 mg or 100 mg round, white debossed tablets. Each tablet, in addition to the active ingredient, contains the following inactive ingredients: carboxymethylcellulose calcium, corn starch, hypromellose, magnesium stearate and microcrystalline cellulose. CLINICAL PHARMACOLOGY Mechanism of Action The mechanism of the effects of Cilostazol Tablets, USP on the symptoms of intermittent claudication is not fully understood. Cilostazol Tablets, USP and several of its metabolities are cyclic AMP (cAMP) phosphodiesterase III inhibitors (PDE III inhibitors), inhibiting phosphodiesterase activity and suppressing cAMP degration with a resultant increase in cAMP in platelets and blood vessels, leading to inhibition of platelet aggregation and vasodilation, respectively.
    [Show full text]
  • Guideline for Preoperative Medication Management
    Guideline: Preoperative Medication Management Guideline for Preoperative Medication Management Purpose of Guideline: To provide guidance to physicians, advanced practice providers (APPs), pharmacists, and nurses regarding medication management in the preoperative setting. Background: Appropriate perioperative medication management is essential to ensure positive surgical outcomes and prevent medication misadventures.1 Results from a prospective analysis of 1,025 patients admitted to a general surgical unit concluded that patients on at least one medication for a chronic disease are 2.7 times more likely to experience surgical complications compared with those not taking any medications. As the aging population requires more medication use and the availability of various nonprescription medications continues to increase, so does the risk of polypharmacy and the need for perioperative medication guidance.2 There are no well-designed trials to support evidence-based recommendations for perioperative medication management; however, general principles and best practice approaches are available. General considerations for perioperative medication management include a thorough medication history, understanding of the medication pharmacokinetics and potential for withdrawal symptoms, understanding the risks associated with the surgical procedure and the risks of medication discontinuation based on the intended indication. Clinical judgement must be exercised, especially if medication pharmacokinetics are not predictable or there are significant risks associated with inappropriate medication withdrawal (eg, tolerance) or continuation (eg, postsurgical infection).2 Clinical Assessment: Prior to instructing the patient on preoperative medication management, completion of a thorough medication history is recommended – including all information on prescription medications, over-the-counter medications, “as needed” medications, vitamins, supplements, and herbal medications. Allergies should also be verified and documented.
    [Show full text]
  • MEDICINE to TREAT: HEART DISEASES Antiplatelet Agents Aspirin Dipyridamole Clopidogrel Ticlopidine 1. What Are These Medicines U
    PATIENT INFORMATION LEAFLET MEDICINE TO TREAT: HEART DISEASES Antiplatelet Agents Aspirin Dipyridamole Clopidogrel Ticlopidine 1. What are these medicines used for? Medicine Purpose of medicine Brand Names This medicine makes blood less sticky to reduce the chance of blood forming Aspirin Cardiprin® clots which will lead to stroke or heart Disprin® attack. This medicine makes the blood less Dipyridamole sticky to reduce the chance of stroke. It Persantin® is used together with aspirin. These medicines make your blood less Clopidogrel (Plavix®) Clopidogrel sticky to reduce chance of stroke or Ticlopidine (Ticlid®), Ticlopidine heart attack. They can be used alone or together with aspirin. 2. How should I take the medicines? • Do not stop taking your medicines without checking with your doctors. • If you miss a dose, take the missed dose as soon as you remember. If it is almost time for your next dose, take only the usual dose. Do not double your dose or use extra medicine to make up for the missed dose. • You should take your medicine after a meal to prevent stomach upset. • How you take aspirin depends on the brand and type of aspirin the doctor gives you: o For tablets which can be chewed: Take with food or glass of water or milk These tablets may be chewed or swallowed whole The solution may also be used as a gargle. Please check with your pharmacist on how to use it as a gargle. o For tablets which enteric coated: Enteric coated forms of aspirin reduce stomach upset that is caused by the medicine Take with a glass of water after food.
    [Show full text]
  • Pharmacokinetic Characteristics of Cilostazol 200 Mg Controlled
    2016;24(4):183-188 TCP Transl Clin Pharmacol http://dx.doi.org/10.12793/tcp.2016.24.4.183 Pharmacokinetic characteristics of cilostazol 200 mg controlled-release tablet compared with two cilostazol 100 mg immediate-release tablets (Pletal) after single oral dose in healthy Korean male volunteers ORIGINAL ARTICLE Jin Dong Son1,4, Sang Min Cho2, Youn Woong Choi2, Soo-Hwan Kim3, In Sun Kwon4, Eun-Heui Jin4, Jae Woo Kim4 and Jang Hee Hong1,4,5* 1Department of Medical Science, College of Medicine, Chungnam National University, Daejeon 35015, republic of Korea, 2Korea Unit- ed Pharm.Inc., Seoul 06116, Republic of Korea, 3Caleb Multilab Inc., Seoul 06745, Republic of Korea, 4Clinical Trials Center, Chun- gnam National University Hospital, Daejeon 35015, South Korea, 5Department of Pharmacology, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea *Correspondence: J.H. Hong; Tel: +82-42-280-6940, Fax: +82-42-280-6940, E-mail: [email protected] Received 8 Sep 2016 Cilostazol controlled-release (CR) tablets have recently been developed by Korea United Pharm Revised 28 Nov 2016 (Seoul, Korea). The tablets use a patented double CR system, which improves drug compliance by Accepted 29 Nov 2016 allowing “once daily” administration and reduces adverse events by sustaining a more even plasma Keywords concentration for 24 h. We conducted an open, randomized, two-period, two-treatment, cross- Cilostazol, OPC-13015, over study to compare the pharmacokinetic (PK) characteristics and tolerability of cilostazol when OPC-13213, administered to healthy Korean male volunteers as CR or immediate release (IR) tablets (Pletal, bioequivalence, Korea Otsuka Pharmaceutical Co., Gyeonggi-do, Korea).
    [Show full text]